LoginSignup
image de profil
Aktien Stammtisch
@Aktien_Stammtisch
1Mo·

$ABBV (+1,12 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (+0,75 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commentaires
Sebastian B.@Baisse-Jumper
1Mo
Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
•
9
•
image de profil
Iwas M.@SSIT
1Mo
If AbbVie goes down even further, I might spontaneously get in today ^^
•
3
•
Voir toutes les 4 autres réponses
image de profil
Thomas@WolfofNersingen
1Mo
Am in
•
2
•
image de profil
Vertriebsliebhaber@Vertriebsliebhaber
1Mo
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
•
2
•
image de profil
Saschko@WarrenamBuffet
1Mo
stupid :(
••
image de profil
Stefan@Slucks87
1Mo
Gut :)
••
Proolix@Proolix
1Mo
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
••
Participez à la conversation
S'inscrireConnexion